263 related articles for article (PubMed ID: 26267042)
1. Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.
Ugel S; Facciponte JG; De Sanctis F; Facciabene A
Cancer Immunol Immunother; 2015 Oct; 64(10):1339-48. PubMed ID: 26267042
[TBL] [Abstract][Full Text] [Related]
2. Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.
Facciponte JG; Ugel S; De Sanctis F; Li C; Wang L; Nair G; Sehgal S; Raj A; Matthaiou E; Coukos G; Facciabene A
J Clin Invest; 2014 Apr; 124(4):1497-511. PubMed ID: 24642465
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
4. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
[TBL] [Abstract][Full Text] [Related]
5. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
6. Endosialin: molecular and functional links to tumor angiogenesis.
Kontsekova S; Polcicova K; Takacova M; Pastorekova S
Neoplasma; 2016; 63(2):183-92. PubMed ID: 26774137
[TBL] [Abstract][Full Text] [Related]
7. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
8. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature.
Rybinski K; Imtiyaz HZ; Mittica B; Drozdowski B; Fulmer J; Furuuchi K; Fernando S; Henry M; Chao Q; Kline B; Albone E; Wustner J; Lin J; Nicolaides NC; Grasso L; Zhou Y
Oncotarget; 2015 Sep; 6(28):25429-40. PubMed ID: 26327620
[TBL] [Abstract][Full Text] [Related]
9. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
10. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.
Lu S; Gan L; Lu T; Zhang K; Zhang J; Wu X; Han D; Xu C; Liu S; Yang F; Qin W; Wen W
Theranostics; 2024; 14(1):379-391. PubMed ID: 38164138
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
12. Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.
Wood LM; Pan ZK; Guirnalda P; Tsai P; Seavey M; Paterson Y
Cancer Immunol Immunother; 2011 Jul; 60(7):931-42. PubMed ID: 21431419
[TBL] [Abstract][Full Text] [Related]
13. A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model.
Yoneyama S; Okaji Y; Tsuno NH; Kawai K; Yamashita H; Tsuchiya T; Yamada J; Sunami E; Osada T; Kitayama J; Takahashi K; Nagawa H
Eur J Surg Oncol; 2007 Dec; 33(10):1191-8. PubMed ID: 17314028
[TBL] [Abstract][Full Text] [Related]
14. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
Yang P; Meng M; Zhou Q
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
[TBL] [Abstract][Full Text] [Related]
16. Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.
Li C; Chacko AM; Hu J; Hasegawa K; Swails J; Grasso L; El-Deiry WS; Nicolaides N; Muzykantov VR; Divgi CR; Coukos G
Cancer Biol Ther; 2014 Apr; 15(4):443-51. PubMed ID: 24553243
[TBL] [Abstract][Full Text] [Related]
17. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.
Shemesh CS; Hsu JC; Hosseini I; Shen BQ; Rotte A; Twomey P; Girish S; Wu B
Mol Ther; 2021 Feb; 29(2):555-570. PubMed ID: 33038322
[TBL] [Abstract][Full Text] [Related]
18. Immunogene therapy.
Lichtor T; Glick RP
Adv Exp Med Biol; 2012; 746():151-65. PubMed ID: 22639166
[TBL] [Abstract][Full Text] [Related]
19. CD248 facilitates tumor growth via its cytoplasmic domain.
Maia M; DeVriese A; Janssens T; Moons M; Lories RJ; Tavernier J; Conway EM
BMC Cancer; 2011 May; 11():162. PubMed ID: 21549007
[TBL] [Abstract][Full Text] [Related]
20. Vaccines targeting tumor vasculature: a new approach for cancer immunotherapy.
Croix BS
Cytotherapy; 2007; 9(1):1-3. PubMed ID: 17354097
[No Abstract] [Full Text] [Related]
[Next] [New Search]
